Libreria Herrero Books :: RARE DISEASE DRUG DEVELOPMENT
error
Divisa

RARE DISEASE DRUG DEVELOPMENT

CLINICAL, SCIENTIFIC, PATIENT, AND CAREGIVER PERSPECTIVES

9783030786045 ::  RARE DISEASE DRUG DEVELOPMENT
ISBN:

9783030786045

EditorialSPRINGER NATURE
Edicion:
Páginas:409
Idioma:INGLES
P.V.P.: 39,99 € + 4% IVA = 41,59 €
Dto 5% Ahorras 2,08 €
Importe final iva incl. 39,51 €
PLAZO DE ENTREGA 15 DIAS

<P>THIS BOOK PROVIDES A BROAD OVERVIEW OF RARE DISEASE DRUG DEVELOPMENT. IT OFFERS UNIQUE INSIGHTS FROM VARIOUS PERSPECTIVES, INCLUDING THIRD-PARTY CAPITAL PROVIDERS, CAREGIVERS, PATIENT ADVOCACY GROUPS, DRUG DEVELOPMENT PROFESSIONALS, MARKETING AND COMMERCIAL EXPERTS, AND PATIENTS.&NBSP;</P><P>A UNIQUE REFERENCE, THE BOOK BEGINS WITH NARRATIVES ON THE MANY CHALLENGES FACED BY RARE DISEASE PATIENT AND THEIR CAREGIVERS. SUBSEQUENT CHAPTERS UNDERSCORE THE CRITICAL, MULTIDIMENSIONAL ROLE OF PATIENT ADVOCACY GROUPS AND THE NOVEL APPROACHES TO RELATED CLINICAL TRIALS, INVESTMENT DECISIONS, AND THE OPTIMIZATION OF RARE DISEASE REGISTRIES. THE BOOK ADDRESSES VARIOUS RARE DISEASE DRUG DEVELOPMENT PROCESSES BY DISCIPLINES SUCH AS ONCOLOGY, HEMATOLOGY, PEDIATRICS, AND GENE THERAPY. CHAPTERS THEN ADDRESS THE OPERATIONAL ASPECTS OF DRUG DEVELOPMENT, INCLUDING APPROVAL PROCESSES, DEVELOPMENT ACCELERATIONS, AND MARKET ACCESS STRATEGIES. THE BOOK CONCLUDES WITH REFLECTIONS ON THE AUTHORS' CASE FOR REAL-WORLD DATA AND EVIDENCE GENERATION IN ORPHAN MEDICINAL DRUG DEVELOPMENT.&NBSP;</P><P><I>RARE DISEASE DRUG DEVELOPMENT</I> IS AN EXPERTLY WRITTEN TEXT OPTIMIZED FOR BIOPHARMACEUTICAL R&D EXPERTS, COMMERCIAL EXPERTS, THIRD-PARTY CAPITAL PROVIDERS, PATIENT ADVOCACY GROUPS, PATIENTS, AND CAREGIVERS.</P>

<P>1.&NBSP;&NBSP;&NBSP;&NBSP;&NBSP;&NBSP;&NBSP;&NBSP;&NBSP;&NBSP;&NBSP; INTRODUCTION TO RARE DISEASES AND MARKET OVERVIEW – RAYMOND A. HUML, MS, DVM, RAC</P><P>2.&NBSP;&NBSP;&NBSP;&NBSP;&NBSP;&NBSP;&NBSP;&NBSP;&NBSP;&NBSP;&NBSP; THE PATIENT PERSPECTIVE - MEREDITH HUML</P><P>3.&NBSP;&NBSP;&NBSP;&NBSP;&NBSP;&NBSP;&NBSP;&NBSP;&NBSP;&NBSP;&NBSP; THE CAREGIVER PERSPECTIVE - PAT FURLONG, RN</P><P>4.&NBSP;&NBSP;&NBSP;&NBSP;&NBSP;&NBSP;&NBSP;&NBSP;&NBSP;&NBSP;&NBSP; THE CRITICAL ROLE OF PATIENT ADVOCACY GROUPS - KERI MCDONOUGH, MA</P><P>5.&NBSP;&NBSP;&NBSP;&NBSP;&NBSP;&NBSP;&NBSP;&NBSP;&NBSP;&NBSP;&NBSP; A MENTAL HEALTH PERSPECTIVE - MICHELLE BAILEY, MD, MPH</P><P>6.&NBSP;&NBSP;&NBSP;&NBSP;&NBSP;&NBSP;&NBSP;&NBSP;&NBSP;&NBSP;&NBSP; INVESTMENT DECISIONS RELATED TO RARE DISEASE DRUG DEVELOPMENT - JONATHAN TUNNICLIFFE, MS, MBA AND DEVIN ROSENTHAL, PHD, MBA</P><P>7.&NBSP;&NBSP;&NBSP;&NBSP;&NBSP;&NBSP;&NBSP;&NBSP;&NBSP;&NBSP;&NBSP; OPTIMIZING RARE DISEASE REGISTRIES AND NATURAL HISTORY STUDIES – SHARON HESTERLEE, PHD</P><P>8.&NBSP;&NBSP;&NBSP;&NBSP;&NBSP;&NBSP;&NBSP;&NBSP;&NBSP;&NBSP;&NBSP; INNOVATIVE CLINICAL TRIAL DESIGN - ZORAN ANTONIJEVIC, MS, AND JONATHAN R. HUML</P><P>9.&NBSP;&NBSP;&NBSP;&NBSP;&NBSP;&NBSP;&NBSP;&NBSP;&NBSP;&NBSP;&NBSP; CNS RARE DISEASE DRUG DEVELOPMENT – JANE WILLIAMS, MD, MPH</P>10.&NBSP;&NBSP;&NBSP;&NBSP;&NBSP;&NBSP;&NBSP;&NBSP;&NBSP; ONCOLOGIC RARE DISEASE DRUG DEVELOPMENT – LAURA VIDAL, MD AND JOZSEF PALATKA, MD<P></P><P>11.&NBSP;&NBSP;&NBSP;&NBSP;&NBSP;&NBSP;&NBSP;&NBSP;&NBSP; HEMATOLOGIC RARE DISEASE DRUG DEVELOPMENT – DANIEL MAZZOLENIS, MD AND LIAT VIDAL, MD</P><P>12.&NBSP;&NBSP;&NBSP;&NBSP;&NBSP;&NBSP;&NBSP;&NBSP;&NBSP; OPHTHALMIC RARE DISEASE DRUG DEVELOPMENT – NICK SPITTAL, MBA</P><P>13.&NBSP;&NBSP;&NBSP;&NBSP;&NBSP;&NBSP;&NBSP;&NBSP;&NBSP; PEDIATRIC CHALLENGES AND ISSUES –ALEXANDER CVETKOVIC MUNTAÑOLA, MD</P><P>14.&NBSP;&NBSP;&NBSP;&NBSP;&NBSP;&NBSP;&NBSP;&NBSP;&NBSP; CELL AND GENE THERAPY - PETER ROBINSON, MBA</P><P>15.&NBSP;&NBSP;&NBSP;&NBSP;&NBSP;&NBSP;&NBSP;&NBSP;&NBSP; THE FEASIBILITY ASSESSMENT – GLORIA ALLEY, RN AND MARIE EMMS</P><P>16.&NBSP;&NBSP;&NBSP;&NBSP;&NBSP;&NBSP;&NBSP;&NBSP;&NBSP; THE EVOLVING REGULATORY SPACE – AND THE ADVENT OF PATIENT FOCUSED DRUG DEVELOPMENT - ANNIE KENNEDY AND JAMES VALENTINE, JD, MHS</P><P>17.&NBSP;&NBSP;&NBSP;&NBSP;&NBSP;&NBSP;&NBSP;&NBSP;&NBSP; OPERATIONAL ASPECTS RELATED TO RARE DISEASE DRUG DEVELOPMENT – CINZIA DORIGO, PHARMD</P><P>18.&NBSP;&NBSP;&NBSP;&NBSP;&NBSP;&NBSP;&NBSP;&NBSP;&NBSP; ACCELERATING RARE DISEASE DRUG DEVELOPMENT IN LIGHT OF COVID-19 – ZIZI IMATORBHEBHE, MS, MBA, PMP</P><P>19.&NBSP;&NBSP;&NBSP;&NBSP;&NBSP;&NBSP;&NBSP;&NBSP;&NBSP; RARE DISEASE DRUG APPROVALS: LESSONS LEARNED – RAYMOND A. HUML, MS, DVM, RAC</P><P>20.&NBSP;&NBSP;&NBSP;&NBSP;&NBSP;&NBSP;&NBSP;&NBSP;&NBSP; COMMERCIAL AND REIMBURSEMENT CHALLENGES – MARYNA KOLOCHAVINA, PHARMD</P><P>21.&NBSP;&NBSP;&NBSP;&NBSP;&NBSP;&NBSP;&NBSP;&NBSP;&NBSP; INTEGRATED LIFE CYCLE MANAGEMENT – MARYNA KOLOCHAVINA, PHARMAD</P><P>22.&NBSP;&NBSP;&NBSP;&NBSP;&NBSP;&NBSP;&NBSP;&NBSP;&NBSP; THE CASE FOR REAL WORLD EVIDENCE IN ORPHAN DRUG DEVELOPMENT – DAVID THOMPSON, PHD AND MARYNA KOLOCHAVINA, PHARMD</P><P>23.&NBSP;&NBSP;&NBSP;&NBSP;&NBSP;&NBSP;&NBSP;&NBSP;&NBSP; SUMMARY & INTEGRATION OF RARE DISEASE DRUG DEVELOPMENT CONCEPTS – RAYMOND A. HUML, MS, DVM, RAC</P>

ANALISIS CLINICOS
BIOLOGIA
BIOLOGIA CELULAR
BIOQUIMICA / BIOLOGIA MOLECULAR
FARMACOLOGIA
INMUNOLOGIA
MEDICINA PREVENTIVA
PSICOLOGIA
TERMINOLOGIA MEDICA
Libros relacionados
ISBN: 9780128222904 DISORDERS OF EMOTION IN NEUROLOGIC DISEASEDISORDERS OF EMOTION IN NEUROLOGIC ... Volumen: 183
9780128222904
Enero 2022

Oferta estudiantes

240€ S/I
228,00€ S/I

ISBN: 9783030574024 ENCYCLOPEDIA OF MOLECULAR PHARMACOLOGYENCYCLOPEDIA OF MOLECULAR PHARMACOLOGY
9783030574024
Enero 2022

1.510,24€ S/I

ISBN: 9783030574000 ENCYCLOPEDIA OF MOLECULAR PHARMACOLOGYENCYCLOPEDIA OF MOLECULAR PHARMACOLOGY
9783030574000
Diciembre 2021

899.99€ S/I
854,99€ S/I

ISBN: 9783030798079 NANOTOXICOLOGY IN HUMANS AND THE ENVIRONMENTNANOTOXICOLOGY IN HUMANS AND THE ...
9783030798079
Diciembre 2021

149.99€ S/I
142,49€ S/I

ISBN: 9783030804916 CELL BIOLOGY AND TRANSLATIONAL MEDICINE, VOLUME 14CELL BIOLOGY AND TRANSLATIONAL ... Volumen: 1347
9783030804916
Diciembre 2021

139.99€ S/I
132,99€ S/I